Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxybuprocaine + fluorescein
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Oxybuprocaine + fluorescein is a fixed-dose combination ophthalmic solution used for diagnostic procedures requiring both local anesthesia and corneal staining, such as Goldmann applanation tonometry and the removal of foreign bodies. Oxybuprocaine is an ester-type local anesthetic that reversibly blocks voltage-gated sodium channels on nerve membranes, inhibiting the conduction of sensory impulses from the cornea and conjunctiva to provide rapid, short-acting surface anesthesia. Fluorescein sodium is a diagnostic dye that stains areas of epithelial loss and fluoresces under cobalt blue light, facilitating the assessment of tear film stability and corneal integrity. The Medical University of Vienna has specifically investigated the impact of different formulations of this combination, including preservative-free single-dose units (SDU) and preserved multi-dose units (MDU), on tear film thickness and ocular surface health in healthy subjects.
- Brand names
- ThilorbinMinims Oxybuprocaine and Fluorescein
- Other names
- Oxybuprocaine/fluorescein SDUOxybuprocaine hydrochloride + fluorescein sodium
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on oxybuprocaine + fluorescein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxybuprocaine + fluorescein.